NZX-listed Cannasouth has exported its first commercial shipment of cannabis-based active pharmaceutical ingredients (API) to Australia. 

Novachem will distribute the firm’s API and finished products to Australian manufacturers, pharmacies and patients.

Mark Lucas

Cannasouth CEO Mark Lucas described the shipment as a significant milestone for the domestic industry, “highlighting the international demand for high-quality, PIC/s Good Manufacturing Practice (GMP)-certified pharmaceutical ingredients”. 

He added: “This sets the stage for the next phase of growth for Cannasouth and the industry.

“Following our first commercial export of cannabis flower to Australia in June, we’re now making significant strides in the Australian medicinal cannabis market by expanding our product offering with the supply of high-purity, verified pharmaceutical CBD ingredients.”

Lucas said upcoming improvements to New Zealand’s medicinal cannabis scheme – expected by the end of the year – “will further enable us to export at scale”. 

Both the firm’s manufacturing facilities now have GMP status. Cannasouth merged with Eqalis Group earlier this year.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...

Leave a comment